# Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

> **NCT04794699** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **IDEAYA Biosciences** · enrollment: 169 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** IDE397
- **DRUG:** Sacituzumab govitecan

## Key facts

- **NCT ID:** NCT04794699
- **Lead sponsor:** IDEAYA Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-14
- **Primary completion:** 2027-01-07
- **Final completion:** 2027-02-04
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04794699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04794699, "Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04794699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*